AEterna Zentaris, Inc. is a late-stage drug development company, which specializes in oncology and endocrine therapy. The company investigates treatments for various cancers which includes colorectal, multiple myeloma, endometrial, ovarian, bladder cancer and prostate. Its pipeline encompasses compounds at all stages of development from drug discovery through marketed products. The company focuses on the development of perifosine, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.